Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423575 | 0.89 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL178687 | 0.89 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29397906 | 0.89 | KMT2A (0.81) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL3140809 | 0.87 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL13525077 | 0.87 | KMT2A (0.73) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29587296 | 0.84 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL18429473 | 0.84 | KMT2A (0.68) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL4553478 | 0.83 | KMT2A (0.63) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL21332462 | 0.82 | KMT2A (0.66) | KMT2AEPHX2CASP3FABP5FABP7 | |
| SCHEMBL29370234 | 0.82 | KMT2A (0.90) | KMT2AEPHX2CASP3FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, KDR | KMT2A 3488/4885EPHX2 568/4885CASP3 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.